Stay updated with breaking news from Alana mcnulty. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
by Kyle LaHucik | May 27, 2021 10:50am EFFECTOR Therapeutics will hit the stock market by merging with blank check company Locust Walk Acquisition. (Getty Images) In a sign of the SPAC times, eFFECTOR Therapeutics was one of a whopping 90-plus biotech assets to be scouted by just one blank check company. The clinical-stage biotech, which is focused on selective translation regulation inhibitors (STRIs) in cancer, ended up persevering in the battle to go public. EFFECTOR and Locust Walk Acquisition Corp. today announced their merger deal, coming amid a major boom recently followed by a slowdown in special purpose acquisition company filings and deals following recent comments by the Securities and Exchange Commission. Locust Walk, which completed its IPO in January, is led by Chris Ehrlich, who has been on the board of multiple acquired biotechs including Amgen’s KAI Pharmaceuticals and Stryker’s Biomimetic ....